Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2930 Monotherapy or Combination in HER2-Positive Breast Cancer
NCT06202261Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2023; status: recruiting.
02
Drugs
TQB2930
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06202261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202261.